Genmab announced its largest acquisition, purchasing Merus for approximately $8 billion in cash. The deal centers on Merus’s lead asset, petosemtamab, an EGFRxLGR5 bispecific antibody with breakthrough therapy designations for head and neck squamous cell carcinoma. The acquisition accelerates Genmab’s transition to a wholly owned model, broadening its oncology pipeline with anticipated multiple drug launches by 2027. Merus gains access to Genmab’s resources to maximize commercial potential. The transaction highlights the growing importance and validation of bispecific antibody therapies in cancer treatment.